Concepedia

Hirotoshi Yuasa

HY

Statistics

Publications

10

Citations

329

H-Index

10

Active since

2012

Affiliations

Pfizer (Japan)(Current)

Pfizer (United States)

Kitasato University

Keio University

Tokyo Medical and Dental University

Hirotoshi Yuasa is an author at Pfizer (Japan) specializing in pharmacotherapy, medicine, and rheumatology.

ORCID

Publications per year

2012–2022

10

Publications

10

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi et al. · Arthritis Research & Therapy · 2016 · 154 citations · Full text

, , +13

A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis

Tsutomu Takeuchi, Nobuyuki Miyasaka, Chuanbo Zang et al. · Modern Rheumatology · 2012 · 38 citations

, , +15

A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis

Tsutomu Takeuchi, Nobuyuki Miyasaka, Chuanbo Zang et al. · Modern Rheumatology · 2013 · 32 citations

, , +15

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim et al. · Intestinal Research · 2018 · 26 citations · Full text

, , +17

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

Yoshiya Tanaka, Naonobu Sugiyama, Shigeyuki Toyoizumi et al. · Lara D. Veeken · 2018 · 17 citations · Full text

, , +13

1–5 of 10